{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:40:33Z","timestamp":1791618033436,"version":"4.3.4"},"reference-count":169,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Heart has a recognized endocrine function as it produces several biologically active substances with hormonal properties. Among these hormones, the natriuretic peptide (NP) system has been extensively characterized and represents a prominent expression of the endocrine function of the heart. Over the years, knowledge about the mechanisms governing their synthesis, secretion, processing, and receptors interaction of NPs has been intensively investigated. Their main physiological endocrine and paracrine effects on cardiovascular and renal systems are mostly mediated through guanylate cyclase-A coupled receptors. The potential role of NPs in the pathophysiology of heart failure and particularly their counterbalancing action opposing the overactivation of renin-angiotensin-aldosterone and sympathetic nervous systems has been described. In addition, NPs are used today as key biomarkers in cardiovascular diseases with both diagnostic and prognostic significance. On these premises, multiple therapeutic strategies based on the biological properties of NPs have been attempted to develop new cardiovascular therapies. Apart from the introduction of the class of angiotensin receptor\/neprilysin inhibitors in the current management of heart failure, novel promising molecules, including M-atrial natriuretic peptide (a novel atrial NP-based compound), have been tested for the treatment of human hypertension. The development of new drugs is currently underway, and we are probably only at the dawn of novel NPs-based therapeutic strategies. The present article also provides an updated overview of the regulation of NPs synthesis and secretion by microRNAs and epigenetics as well as interactions of cardiac hormones with other endocrine systems.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehac759","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T06:21:46Z","timestamp":1672381306000},"page":"643-655","source":"Crossref","is-referenced-by-count":43,"title":["Endocrine functions of the heart: from bench to bedside"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-8380","authenticated-orcid":false,"given":"Massimo","family":"Volpe","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome , Via di Grottarossa 1035, 00189 Rome , Italy"},{"name":"IRCCS San Raffaele , Via della Pisana 235, 00163 Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-117X","authenticated-orcid":false,"given":"Giovanna","family":"Gallo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome , Via di Grottarossa 1035, 00189 Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Speranza","family":"Rubattu","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome , Via di Grottarossa 1035, 00189 Rome , Italy"},{"name":"IRCCS Neuromed , Via Atinense 18, 86077 Pozzilli (IS) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.ackd.2004.07.003","article-title":"Emergence of the concept of endocrine function and endocrinology","volume":"11","author":"Eknoyan","year":"2004","journal-title":"Adv Chronic Kidney Dis"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s004180050245","article-title":"Camillo Golgi and the discovery of the Golgi apparatus","volume":"109","author":"Dr\u00f6scher","year":"1998","journal-title":"Histochem Cell Biol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1083\/jcb.23.1.101","article-title":"New cytoplasmic components in arterial endothelia","volume":"23","author":"Weibel","year":"1964","journal-title":"J Cell Biol"},{"key":"2023022023593452300_","first-page":"99","article-title":"Electron microscopy of the atrium of the heart. I. Guinea pig","volume":"14","author":"Kisch","year":"1956","journal-title":"Exp Med Surg"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/01.RES.4.1.85","article-title":"Evidence of the atrial location of receptors influencing urine flow","volume":"4","author":"Henry","year":"1956","journal-title":"Circ Res"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0024-3205(81)90370-2","article-title":"A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats","volume":"28","author":"de Bold","year":"1981","journal-title":"Life Sci"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/cvr\/7.3.351","article-title":"Studies on the relationship between the catecholamine distribution in the atrium and the specific granules present in atrial muscle cells. 1. Isolation of a purified specific granule subfraction","volume":"7","author":"De Bold","year":"1973","journal-title":"Cardiovasc Res"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3181\/00379727-161-40584","article-title":"Heart atria granularity effects of changes in water-electrolyte balance","volume":"161","author":"De Bold","year":"1979","journal-title":"Proc Soc Exp Biol Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.RES.67.3.774","article-title":"Angiotensin II-induced atrial natriuretic factor release in dogs is not related to hemodynamic responses","volume":"67","author":"Volpe","year":"1990","journal-title":"Circ Res"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/01.RES.63.2.322","article-title":"Hemodynamic responses to atrial natriuretic factor in nephrectomized rabbits: attenuation of the circulatory consequences of acute volume expansion","volume":"63","author":"Volpe","year":"1988","journal-title":"Circ Res"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.8.4.312","article-title":"Cardiovascular effects of atrial natriuretic factor in anesthetized and conscious dogs","volume":"8","author":"Kleinert","year":"1986","journal-title":"Hypertension"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"I43","DOI":"10.1161\/01.HYP.7.3_Pt_2.I43","article-title":"Effect of atrial natriuretic factor on blood pressure, renin, and aldosterone in Goldblatt hypertension","volume":"7","author":"Volpe","year":"1985","journal-title":"Hypertension"},{"key":"2023022023593452300_","first-page":"F863","article-title":"Effects of synthetic atrial natriuretic factor on renal function and renin release","volume":"247","author":"Burnett","year":"1984","journal-title":"Am J Physiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0735-1097(87)80271-1","article-title":"Hemodynamic and hormonal effects of atrial natriuretic factor in patients with essential hypertension","volume":"10","author":"Volpe","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1172\/JCI112723","article-title":"Atrial natriuretic factor in Normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion","volume":"78","author":"Cody","year":"1986","journal-title":"J Clin Invest"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur Heart J"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-007-9016-3","article-title":"Natriuretic peptides and therapeutic applications","volume":"12","author":"Lee","year":"2007","journal-title":"Heart Fail Rev"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0008-6363(95)00121-2","article-title":"Mechanical and neuroendocrine regulation of the endocrine heart","volume":"31","author":"de Bold","year":"1996","journal-title":"Cardiovas Res"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jacbts.2020.05.007","article-title":"Cardiac endocrinology: heart-derived hormones in physiology and disease","volume":"5","author":"Zhao","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.tem.2005.10.007","article-title":"The endocrine function of the heart","volume":"16","author":"McGrath","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/CIRCGENETICS.109.877456","article-title":"Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome","volume":"3","author":"Eggers","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","article-title":"Growth differentiation factor 15 as a biomarker in cardiovascular disease","volume":"63","author":"Wollert","year":"2017","journal-title":"Clin Chem"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCULATIONAHA.112.115089","article-title":"Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models","volume":"126","author":"Ogura","year":"2012","journal-title":"Circulation"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000486127","article-title":"Serum FGF21 is associated with future cardiovascular events in patients with coronary artery disease","volume":"139","author":"Shen","year":"2018","journal-title":"Cardiology"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"33953","DOI":"10.1038\/srep33953","article-title":"Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction","volume":"6","author":"Chou","year":"2016","journal-title":"Sci Rep"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/ncomms3019","article-title":"Fibroblast growth factor 21 protects against cardiac hypertrophy in mice","volume":"4","author":"Planavila","year":"2013","journal-title":"Nat Commun"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cardiores.2005.06.008","article-title":"Mechanisms of atrial natriuretic peptide secretion from the atrium","volume":"68","author":"Dietz","year":"2005","journal-title":"Cardiovasc Res"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1373\/clinchem.2010.143883","article-title":"Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases","volume":"56","author":"Semenov","year":"2010","journal-title":"Clin Chem"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/187152907780059128","article-title":"Discovery of new cardiovascular hormones for the treatment of congestive heart failure","volume":"7","author":"Vesely","year":"2007","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"691407","DOI":"10.3389\/fphys.2021.691407","article-title":"Atrial natriuretic peptide31\u201367: a novel therapeutic factor for cardiovascular diseases","volume":"12","author":"da Silva","year":"2021","journal-title":"Front Physiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.peptides.2018.08.006","article-title":"Natriuretic peptides in human heart: novel insight into their molecular forms, functions, and diagnostic use","volume":"111","author":"Matsuo","year":"2019","journal-title":"Peptides"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.amjcard.2017.06.030","article-title":"Differences in natriuretic peptide levels by race\/ethnicity (from the multi-ethnic study of atherosclerosis)","volume":"120","author":"Gupta","year":"2017","journal-title":"Am J Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/CIRCRESAHA.119.315026","article-title":"Race, natriuretic peptides, and high-carbohydrate challenge: a clinical trial","volume":"125","author":"Patel","year":"2019","journal-title":"Circ Res"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/jcm8101746","article-title":"The endocrine function of the heart: physiology and involvements of natriuretic peptides and cyclic nucleotide phosphodiesterases in heart failure","volume":"8","author":"Lugnier","year":"2019","journal-title":"J Clin Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1210\/endo.133.3.8365374","article-title":"Stretch-induced atrial natriuretic factor release utilizes a rapidly depleting pool of newly synthesized hormone","volume":"133","author":"Mangat","year":"1993","journal-title":"Endocrinology"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.humpath.2012.04.023","article-title":"Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy","volume":"44","author":"Frustaci","year":"2013","journal-title":"Hum Pathol"},{"key":"2023022023593452300_","first-page":"1294","article-title":"New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy","volume":"18","author":"Murakami","year":"2002","journal-title":"Can J Cardiol"},{"key":"2023022023593452300_","first-page":"H1684","article-title":"Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure","volume":"274","author":"Luchner","year":"1998","journal-title":"Am J Physiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.healun.2004.06.023","article-title":"Neuroendocrine profiling of humans receiving cardiac allografts","volume":"24","author":"Ogawa","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/01.CIR.100.3.287","article-title":"Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans","volume":"100","author":"Masters","year":"1999","journal-title":"Circulation"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1042\/bj20021087","article-title":"Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1","volume":"370","author":"Chun","year":"2003","journal-title":"Biochem J"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"e006570","DOI":"10.1161\/CIRCHEARTFAILURE.119.006570","article-title":"Inflammation and circulating natriuretic peptide levels","volume":"13","author":"Fish-Trotter","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/hrt.76.3_Suppl_3.36","article-title":"The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides","volume":"76","author":"Richards","year":"1996","journal-title":"Heart"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1128\/MCB.21.4.1173-1184.2001","article-title":"Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1","volume":"21","author":"Clerk","year":"2001","journal-title":"Mol Cell Biol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1007\/s00018-020-03573-0","article-title":"Epigenetic control of natriuretic peptides: implications for health and disease","volume":"77","author":"Rubattu","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/path.4234","article-title":"Epigenetics and chromatin remodeling in adult cardiomyopathy","volume":"231","author":"Mahmoud","year":"2013","journal-title":"J Pathol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI61084","article-title":"HDAC4 controls histone methylation in response to elevated cardiac load","volume":"123","author":"Hohl","year":"2013","journal-title":"J Clin Invest"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fgene.2018.00014","article-title":"The histone demethylase JMJD2A modulates the induction of hypertrophy markers in iPSC-derived cardiomyocytes","volume":"9","author":"Rosales","year":"2018","journal-title":"Front Genet"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.athoracsur.2017.04.046","article-title":"Histone modification is correlated with reverse left ventricular remodeling in nonischemic dilated cardiomyopathy","volume":"104","author":"Ito","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"785731","DOI":"10.1155\/2013\/785731","article-title":"Integrative analysis of methylome and transcriptome reveals the importance of unmethylated CpGs in non-CpG island gene activation","volume":"2013","author":"Marx","year":"2013","journal-title":"Biomed Res Int"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13148-020-00927-0","article-title":"Association between NPPA promoter methylation and hypertension: results from Gusu cohort and replication in an independent sample","volume":"12","author":"Li","year":"2020","journal-title":"Clin Epigenetics"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000521295","article-title":"NPPA promoter hypomethylation predicts central obesity development: a prospective longitudinal study in Chinese adults","volume":"15","author":"Li","year":"2022","journal-title":"Obes Facts"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00438-013-0734-z","article-title":"miRNA-transcription factor interactions: a combinatorial regulation of gene expression","volume":"288","author":"Arora","year":"2013","journal-title":"Mol Genet Genomics"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2015.11.049","article-title":"Acute metabolic influences on the natriuretic peptide system in humans","volume":"67","author":"Arora","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/MCB.01114-15","article-title":"Novel microRNA regulators of atrial natriuretic peptide production","volume":"36","author":"Wu","year":"2016","journal-title":"Mol Cell Biol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/ng.328","article-title":"Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure","volume":"41","author":"Newton-Cheh","year":"2009","journal-title":"Nat Genet"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2011.05.011","article-title":"A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community","volume":"58","author":"Cannone","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.2337\/dc12-2337","article-title":"The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population","volume":"36","author":"Cannone","year":"2013","journal-title":"Diabetes Care"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"e130978","DOI":"10.1172\/jci.insight.130978","article-title":"Antisense regulation of atrial natriuretic peptide expression","volume":"4","author":"Celik","year":"2019","journal-title":"JCI Insight"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"e00271\u201319","DOI":"10.1128\/MCB.00271-19","article-title":"Functional screening identifies microRNA regulators of corin activity and atrial natriuretic peptide biogenesis","volume":"39","author":"Celik","year":"2019","journal-title":"Mol Cell Biol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2003.11.001","article-title":"Autocrine and paracrine actions of natriuretic peptides in the heart","volume":"101","author":"D'Souza","year":"2004","journal-title":"Pharmacol Ther"},{"key":"2023022023593452300_","article-title":"NPPA\/Atrial natriuretic peptide is an extracellular modulator of autophagy in the heart","author":"Forte","year":"2022","journal-title":"Autophagy"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.peptides.2004.09.024","article-title":"Biology of natriuretic peptides and their receptors","volume":"26","author":"Pandey","year":"2005","journal-title":"Peptides"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.3390\/ijms20163874","article-title":"Cardiovascular pleiotropic effects of natriuretic peptides","volume":"20","author":"Forte","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1126\/science.7839143","article-title":"Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension","volume":"267","author":"John","year":"1995","journal-title":"Science"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.bbadis.2009.09.009","article-title":"Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development","volume":"1792","author":"Scott","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jacc.2005.12.081","article-title":"Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension","volume":"48","author":"Rubattu","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1073\/pnas.070371497","article-title":"Cardiac fibrosis in mice lacking brain natriuretic peptide","volume":"97","author":"Tamura","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1242\/dev.100370","article-title":"Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development","volume":"141","author":"Becker","year":"2014","journal-title":"Development"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ajh.2008.174","article-title":"Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases","volume":"21","author":"Rubattu","year":"2008","journal-title":"Am J Hypertens"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/CIRCRESAHA.113.301325","article-title":"C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling","volume":"112","author":"Sciarretta","year":"2013","journal-title":"Circ Res"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1172\/JCI37430","article-title":"The natriuretic peptide\/guanylyl cyclase\u2013a system functions as a stress-responsive regulator of angiogenesis in mice","volume":"119","author":"Kuhn","year":"2009","journal-title":"J Clin Invest"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1161\/HYPERTENSIONAHA.120.15772","article-title":"Heart-microcirculation connection: effects of ANP (atrial natriuretic peptide) on pericytes participate in the acute and chronic regulation of arterial blood pressure","volume":"76","author":"\u0160piranec Spes","year":"2020","journal-title":"Hypertension"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/CIRCULATIONAHA.117.033383","article-title":"Endothelial C-type natriuretic peptide acts on pericytes to regulate microcirculatory flow and blood pressure","volume":"138","author":"\u0160piranec","year":"2018","journal-title":"Circulation"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"10554","DOI":"10.1038\/srep10554","article-title":"The local CNP\/GC-B system in growth plate is responsible for physiological endochondral bone growth","volume":"5","author":"Nakao","year":"2015","journal-title":"Sci Rep"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.116.08219","article-title":"Endothelium-derived C-type natriuretic peptide contributes to blood pressure regulation by maintaining endothelial integrity","volume":"69","author":"Nakao","year":"2017","journal-title":"Hypertension"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1172\/JCI74281","article-title":"Endothelial C-type natriuretic peptide maintains vascular homeostasis","volume":"124","author":"Moyes","year":"2014","journal-title":"J Clin Invest"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/eurheartj\/ehz093","article-title":"C-type natriuretic peptide co-ordinates cardiac structure and function","volume":"41","author":"Moyes","year":"2020","journal-title":"Eur Heart J"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.vph.2009.06.005","article-title":"Enhanced hypertrophy in ob\/ob mice due to an impairment in expression of atrial natriuretic peptide","volume":"51","author":"Mascareno","year":"2009","journal-title":"Vascul Pharmacol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.tem.2007.11.006","article-title":"Control of lipolysis by natriuretic peptides and cyclic GMP","volume":"19","author":"Lafontan","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.2337\/db09-0393","article-title":"Natriuretic peptides\/cGMP\/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity","volume":"58","author":"Miyashita","year":"2009","journal-title":"Diabetes"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116470119","article-title":"C-type natriuretic peptide is a pivotal regulator of metabolic homeostasis","volume":"119","author":"Perez-Ternero","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.2337\/db17-0392","article-title":"Atrial natriuretic peptide affects stimulus-secretion coupling of pancreatic \u03b2-cells","volume":"66","author":"Undank","year":"2017","journal-title":"Diabetes"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0024-3205(93)90141-O","article-title":"Increased concentrations of atrial and plasma atrial natriuretic peptide in castrated Male rats","volume":"52","author":"Hwu","year":"1993","journal-title":"Life Sci"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1152\/ajpheart.00226.2011","article-title":"Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones","volume":"301","author":"Clerico","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI115458","article-title":"Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure","volume":"88","author":"Volpe","year":"1991","journal-title":"J Clin Invest"},{"key":"2023022023593452300_","first-page":"3871","article-title":"Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in Normal man","volume":"81","author":"Hunt","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/01.CIR.84.1.92","article-title":"Abnormal hormonal and renal responses to saline load in hypertensive patients with parental history of cardiovascular accidents","volume":"84","author":"Volpe","year":"1991","journal-title":"Circulation"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jacc.2006.10.063","article-title":"Evidence for functional heterogeneity of circulating B-type natriuretic peptide","volume":"49","author":"Liang","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"e003601","DOI":"10.1161\/JAHA.116.003601","article-title":"MiR30-GALNT1\/2 axis-mediated glycosylation contributes to the increased secretion of inactive human prohormone for brain natriuretic peptide (proBNP) from failing hearts","volume":"6","author":"Nakagawa","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/ki.1996.491","article-title":"Blunted cGMP response to agonists and enhanced glomerular cyclic 3\u2019,5'-nucleotide phosphodiesterase activities in experimental congestive heart failure","volume":"50","author":"Supaporn","year":"1996","journal-title":"Kidney Int"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NOindependent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40292-021-00489-z","article-title":"Targeting cyclic guanylate monophosphate in resistant hypertension and heart failure: are sacubitril\/valsartan and vericiguat synergistic and effective in both conditions?","volume":"28","author":"Gallo","year":"2021","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"e068424","DOI":"10.1136\/bmj-2021-068424","article-title":"Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study","volume":"377","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2009.01.033","article-title":"Human coronary atherosclerosis modulates cardiac natriuretic peptide release","volume":"206","author":"Barbato","year":"2009","journal-title":"Atherosclerosis"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"14909","DOI":"10.1038\/s41598-021-94346-7","article-title":"Joint analysis of D-dimer, N-terminal pro B-type natriuretic peptide, and cardiac troponin I on predicting acute pulmonary embolism relapse and mortality","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12890-017-0521-4","article-title":"The association of N-terminal pro-brain-type natriuretic peptide with hemodynamics and functional capacity in therapy-naive precapillary pulmonary hypertension: results from a cohort study","volume":"17","author":"Berghaus","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"e004851","DOI":"10.1161\/JAHA.116.004851","article-title":"Repeated measurements of cardiac biomarkers in atrial fibrillation and validation of the ABC stroke score over time","volume":"6","author":"Hijazi","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3390\/jcm9072265","article-title":"Natriuretic peptides, cognitive impairment and dementia: an intriguing pathogenic link with implications in hypertension","volume":"9","author":"Gallo","year":"2020","journal-title":"J Clin Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijcard.2011.11.057","article-title":"NT-proANP circulating level is a prognostic marker in stable ischemic heart disease","volume":"155","author":"Barbato","year":"2012","journal-title":"Int J Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"e024616","DOI":"10.1161\/JAHA.121.024616","article-title":"B-type natriuretic peptide and long-term cardiovascular mortality in patients with coronary heart disease","volume":"11","author":"Stewart","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2143\/AC.63.1.2025331","article-title":"Value of peri-procedural B-type natriuretic peptide levels in predicting cardiac events after elective percutaneous coronary intervention","volume":"63","author":"Yildirir","year":"2008","journal-title":"Acta Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.yjmcc.2019.03.011","article-title":"Molecular and clinical implications of natriuretic peptides in aortic valve stenosis","volume":"129","author":"Gallo","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/eurheartj\/ehz892","article-title":"Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry","volume":"41","author":"Chen","year":"2020","journal-title":"Eur Heart J"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/diseases6020033","article-title":"Comparison of brain natriuretic peptide levels to simultaneously obtained right heart hemodynamics in stable outpatients with pulmonary arterial hypertension","volume":"6","author":"Helgeson","year":"2018","journal-title":"Diseases"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3390\/jcm9051348","article-title":"Functional role of natriuretic peptides in risk assessment and prognosis of patients with mitral regurgitation","volume":"9","author":"Gallo","year":"2020","journal-title":"J Clin Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2459\/JCM.0000000000000852","article-title":"Atrial natriuretic peptide predicts disease progression and digital ulcers development in systemic sclerosis patients","volume":"20","author":"Romaniello","year":"2019","journal-title":"J Cardiovasc Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/1744666X.2021.1908888","article-title":"Circulating NT-proANP level is a predictor of mortality for systemic sclerosis: a retrospective study of an Italian cohort","volume":"17","author":"Romaniello","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"e001072","DOI":"10.1136\/openhrt-2019-001072","article-title":"Superiority of proatrial natriuretic peptide in the prognostic power in patients with acute decompensated heart failure on hospital admission: comparison with B-type natriuretic peptide and other natriuretic peptide forms","volume":"6","author":"Takashio","year":"2019","journal-title":"Open Heart"},{"key":"2023022023593452300_","first-page":"196","article-title":"Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy","volume":"106","author":"B\u00e9gu\u00e9","year":"2020","journal-title":"Heart"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart failure association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","article-title":"Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis","volume":"4","author":"Willeit","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/clc.20813","article-title":"Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study","volume":"33","author":"Volpe","year":"2010","journal-title":"Clin Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jacbts.2021.05.001","article-title":"STOP-HF Trial: higher endogenous BNP and cardiovascular protection in subjects at risk for heart failure","volume":"6","author":"Cannone","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cjca.2014.10.022","article-title":"The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications","volume":"31","author":"Moe","year":"2015","journal-title":"Can J Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2014.05.007","article-title":"Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure","volume":"2","author":"Felker","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"Volpe","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A test in context: neprilysin: function, inhibition, and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2020.11.071","article-title":"Sacubitril\/valsartan for the management of heart failure: a perspective viewpoint on current evidence","volume":"327","author":"Volpe","year":"2021","journal-title":"Int J Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1097\/HJH.0000000000001762","article-title":"Effects of dual angiotensin type 1 receptor\/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat","volume":"36","author":"Rubattu","year":"2018","journal-title":"J Hypertens"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchf.2020.09.013","article-title":"Atrial natriuretic peptide and treatment with sacubitril\/valsartan in heart failure with reduced ejection fraction","volume":"9","author":"Murphy","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1161\/01.CIR.93.11.1963","article-title":"Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide","volume":"93","author":"Omland","year":"1996","journal-title":"Circulation"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ejhf.1670","article-title":"Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study","volume":"22","author":"Senni","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"e007034","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034","article-title":"Efficacy and safety of sacubitril\/valsartan in high-risk patients in the PIONEER-HF trial","volume":"14","author":"Berg","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"652163","DOI":"10.3389\/fphys.2021.652163","article-title":"Sacubitril\/valsartan as a therapeutic tool across the range of heart failure phenotypes and ejection fraction Spectrum","volume":"12","author":"Gallo","year":"2021","journal-title":"Front Physiol"},{"key":"2023022023593452300_","author":"Novartis (2021)"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jchf.2015.03.011","article-title":"Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure","volume":"3","author":"Vodovar","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jamacardio.2022.0784","article-title":"Could neprilysin be already inhibited by BNP in the LIFE trial?","volume":"7","author":"Vodovar","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/ejhf.2663","article-title":"Sacubitril\/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial","volume":"24","author":"Berwanger","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/HYPERTENSIONAHA.121.18114","article-title":"Endothelial natriuretic peptide receptor 1 play crucial role for acute and chronic blood pressure regulation by atrial natriuretic peptide","volume":"79","author":"Tokudome","year":"2022","journal-title":"Hypertension"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jacc.2012.05.049","article-title":"Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP","volume":"60","author":"Macheret","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40292-021-00483-5","article-title":"The natriuretic peptides for hypertension treatment","volume":"29","author":"Rubattu","year":"2022","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/HYPERTENSIONAHA.121.17159","article-title":"First-in-Human study of MANP: a novel ANP (atrial natriuretic peptide) analog in human hypertension","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"815796","DOI":"10.3389\/fphys.2021.815796","article-title":"Natriuretic peptides and blood pressure homeostasis: implications for MANP, a novel guanylyl cyclase a receptor activator for hypertension","volume":"12","author":"Cannone","year":"2022","journal-title":"Front Physiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMoa0706300","article-title":"Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation","volume":"359","author":"Hodgson-Zingman","year":"2008","journal-title":"N Engl J Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/HYPERTENSIONAHA.121.18264","article-title":"Novel ANP (atrial natriuretic peptide)-based therapy for hypertension: the promising role of a disease mechanism targeted approach","volume":"78","author":"Volpe","year":"2021","journal-title":"Hypertension"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1161\/HYPERTENSIONAHA.120.14704","article-title":"Cardioprotective effects of the novel compound vastiras in a preclinical model of End-organ damage","volume":"75","author":"Altara","year":"2020","journal-title":"Hypertension"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"650124","DOI":"10.3389\/fphys.2021.650124","article-title":"Toward a new paradigm for targeted natriuretic peptide enhancement in heart failure","volume":"12","author":"Gidl\u00f6f","year":"2021","journal-title":"Front Physiol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/euhj.1998.1201","article-title":"Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition","volume":"19","author":"Newby","year":"1998","journal-title":"Eur Heart J"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(13)70029-9","article-title":"Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial","volume":"1","author":"Parvanova","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCHEARTFAILURE.108.776294","article-title":"The tumultuous journey of nesiritide: past, present, and future","volume":"1","author":"Burnett","year":"2008","journal-title":"Circ Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ehf2.13770","article-title":"Effect of carperitide on the 1 year prognosis of patients with 5 acute decompensated heart failure","volume":"9","author":"Nogi","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ehjcvp\/pvv040","article-title":"Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions","volume":"2","author":"Lee","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40262-021-01059-1","article-title":"Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia","volume":"61","author":"Chan","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.0811851106","article-title":"Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide","volume":"106","author":"Pan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/bc200592c","article-title":"Atrial natriuretic peptide-fc, ANP-fc, fusion proteins: semisynthesis, in vitro activity and pharmacokinetics in rats","volume":"23","author":"Mezo","year":"2012","journal-title":"Bioconjug Chem"},{"key":"2023022023593452300_","first-page":"cvac125","article-title":"Natriuretic peptide pathways in heart failure\u2014further therapeutic possibilities","author":"Sangaralingham","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2023022023593452300_","first-page":"859","article-title":"Natriuretic peptide-based novel therapeutics: long journeys of drug developments optimized for disease states","volume":"11","author":"Ichiki","year":"2022","journal-title":"Biology (Basel)"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109386118","article-title":"Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators","volume":"118","author":"Sangaralingham","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10557-020-06959-1","article-title":"Cardiac cyclic nucleotide phosphodiesterases: roles and therapeutic potential in heart failure","volume":"34","author":"Preedy","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2023022023593452300_","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0014-2999(03)01674-1","article-title":"Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase","volume":"468","author":"Schmidt","year":"2003","journal-title":"Eur J Pharmacol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/8\/643\/49246429\/ehac759.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/8\/643\/49246429\/ehac759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T02:43:33Z","timestamp":1678934613000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/8\/643\/6965387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":169,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,12,30]]},"published-print":{"date-parts":[[2023,2,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac759","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,21]]},"published":{"date-parts":[[2022,12,30]]}}}